- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06619366
The Impact of Coach-guided Risk Communication on the Risk of Major Depression
The Impact of Coach-guided Risk Communication on the Risk of Major Depression: A Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background and importance:
Depression is a highly prevalent and disabling mental health problem. One cost-effective way of reducing the disease burden associated with depression is selective prevention, i.e., identifying individuals who are at high risk of depression, and intervene before it happens. The investigators developed the first sex-specific multivariable risk predictive algorithms (MVRPs) for major depressive episode (MDE) using data from over 10,000 Canadians. Using the MVRP as the foundation and working with future users, the investigators developed a coach-guided personalized depression risk communication tool (PDRC) for sharing information about individualized depression risk, risk profile (risk factors present), potential risk reduction and self-help strategies. It is anticipate that the coach-guided PDRC will greatly motivate users to actively engage in self-help and help-seeking, leading to a reduced risk of depression in the population.
Goals/Research Aims:
The aims of the proposed randomized controlled trial (RCT) are to evaluate the impacts of the coach-guided PDRC on: (1) the risk of MDE at 12 months, (2) self-help and help-seeking behaviors, (3) the severity of depressive symptoms, and to examine (4) the moderation effect by self-efficacy and (5) the cost effectiveness of the coach-guided PDRC.
Methods/Expertise:
The proposed RCT has two arms: (1) intervention group, receiving the coach-guided PDRC; (2) control group, receiving personalized depression risk information. The study population are male and female adults in the community who are at high risk of having an MDE. Because the tools (MVRP) for estimating the risk of having an MDE are sex-specific, the recruitment and the randomization will be conducted in males and females separately. The investigators plan to recruit and follow 500 male and 500 female adults who are at high risk across Canada random digit dialing method and social media and poster advertisement.
The participants will be assessed at baseline, 3- and 12-month to ascertain short-term and mid-term effects. Data will be analyzed in males and females, separately, controlling for the effects of covariates which include gender and gender role related variables. The investigators will examine how the intervention influences the changes in self-help and help seeking behaviors and in depressive symptoms, whether the intervention effect differ by levels of self-efficacy, and if the economic gain exceeds program-related cost. Following the CONSORT guidelines, the investigators will perform both complete case and intent-to-treat analyses based on randomization. The research team has the needed expertise for conducting the proposed RCT, including psychiatry, epidemiology, biostatistics, health economics, risk communication and large RCTs.
The expected outcomes:
In aim 1, it is expected that participants who receive the coach-guided PDRC will have a significantly lower risk of developing MDE over 12 months than those in the control group. It is expected that the intervention will significantly enhance participants' self-help and help-seeking behaviors (aim 2) and reduce depressive symptoms (aim 3). In aim 4, it is expected to observe that the intervention effect is greater in those with higher level of self-efficacy. Finally, the intervention will achieve preferable cost and saving ratio (aim 5). If successful, this coach-guided PDRC can be a novel and cost-effective program for selective prevention of depression in the Canadian general population.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jianli Wang, PhD
- Phone Number: 902-473-6684
- Email: jianli.wang@dal.ca
Study Locations
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 1V7
- Recruiting
- Faculty of medicine
-
Contact:
- JianLi Wang, PhD
- Phone Number: 9024943575
- Email: jianli.wang@dal.ca
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- no MDE at baseline, or full remission for 2 months for those who had a past MDE (see below the question).
- Aged 18 and 65 years.
- At high risk of MDE based on the depression risk calculators (predicted risk of 6.5%+ for males and 11.2%+ for females), which represent the top two deciles of male and female populations in Canada.
- Agreement to be contacted for follow-up assessments, and
- no language barriers to English or French
Exclusion Criteria:
individuals who
- cannot provide informed consent,
- do not agree to be followed,
- cannot communicate in English and French, or
- report suicide behaviors (score >0 on item 9 of the Patient Health Questionnaire (PHQ-9)).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Personalized depression risk communication
The intervention has two integrated components: PDRC and coach-guidance. The PDRC has five sections. The PDRC will be sent to participants by email/mail within two days after the baseline and follow-up assessments. The coach will contact the participant within a week after the PDRC is provided by telephone or video conference, depending on participants' preference. The role of the coach is to assist the participant in understanding and interpreting the PDRC, answering their questions, and helping identify self-help strategies that are feasible for the participant; they do not provide psychotherapy. The coaching session will follow the four processes of motivational interview. |
see information in arm description.
|
|
Active Comparator: Placebo control
Participants in the control group will receive their individualized depression risk information.
Receiving individualized depression risk information is considered as "control" because: (1) our previous RCT showed that receiving individualized depression risk information caused no psychological harm and was effective in reducing distress and improving function; (2) Receiving depression risk information was used as control in our pilot study; (3) The pilot study suggested that the coach-guided PDRC may be more effective than receiving depression risk information alone.
|
see information in arm description.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The proportion of major depressive episode cases
Time Frame: 12 months after randomization.
|
The proportion of new onset major depressive episode cases measured by the Composite International Diagnostic Interview (CIDI).
|
12 months after randomization.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Depressive symptom score
Time Frame: 3 and 12 months
|
depressive symptom score measured by Patient Health Questionnaire-9.
The score ranges between 0 and 27, with a higher score indicating more severe depression.
|
3 and 12 months
|
|
change in self-help behaviors
Time Frame: 3 and 12 months
|
changes in self-help behavioral score measured by the Self-management Strategy Use Scale (SSUS).
The SSUS assesses the frequency of using each of the 14 evidence-based self-help strategies.
Frequency of use is rated on a 5-category scale.
The score ranges between 14 and 70.
A higher score indicates more self-help actions.
|
3 and 12 months
|
|
The percentage of mental health service use
Time Frame: 12 months
|
The percentage of reported use of main stream mental health services
|
12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
anxiety symptom score
Time Frame: 3 and 12 months
|
anxiety symptom score measured by Generalized Anxiety Disorder-7.
The score ranges from 0 to 21.
A higher score indicates more severe anxiety.
|
3 and 12 months
|
|
Cost reduction
Time Frame: 12 months
|
Sick leave and productivity measured by Health and Work Performance Questionnaire which collects information about number of sick leave days and presenteeism in the past 30 days.
The number of sick leave days will be converted into monetary figure to represent cost.
|
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: JianLi Wang, PhD, Dalhousie University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2024-7208
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Self Efficacy
-
Brigham and Women's HospitalNational Institutes of Health (NIH); National Institute on Aging (NIA)CompletedFall Injury | Falls | Exercise Self-Efficacy | Falls Self-EfficacyUnited States
-
Central South UniversityCompletedSelf Efficacy | Self-management
-
IRCCS Policlinico S. DonatoNot yet recruitingSelf Efficacy | Self Confidence | Anticoagulants
-
Kolding SygehusCompleted
-
The New SchoolUniversity of ZurichCompletedSelf EfficacyUnited States
-
Tuğba SarıCompleted
-
Karolinska InstitutetCompleted
-
Pacific Northwest University of Health SciencesAmerican Association of Colleges of Osteopathic Medicine - AACOMCompleted
-
University of Vic - Central University of CataloniaCompleted
-
Chinese University of Hong KongCompleted
Clinical Trials on coach-guided personalized depression risk communication
-
University of CalgaryCanadian Institutes of Health Research (CIHR)Completed
-
Ottawa Hospital Research InstituteCompletedElective Surgical ProceduresCanada
-
University of OxfordNIHR Collaboration for Leadership in Applied Health Research and Care (Oxford)CompletedType 2 Diabetes MellitusUnited Kingdom
-
Memorial Sloan Kettering Cancer CenterNYU College of DentistryActive, not recruitingSmoking CessationUnited States